Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib

J Cancer Res Ther. 2014 Oct-Dec;10(4):1112-4. doi: 10.4103/0973-1482.144564.

Abstract

Transarterial chemoembolization (TACE) has been the standard treatment modality in patients with intermediate stage hepatocellular carcinoma (HCC). Brivanib is an oral small molecular inhibitor of both vascular endothelial growth factor and fibroblast growth factor receptors. Herein, we reported that a 67-year-old patient with intermediate stage HCC achieved the complete remission after TACE combined with brivanib therapy. This finding potentially suggested the benefit of this combination therapy for HCC.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Alanine / analogs & derivatives*
  • Alanine / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy*
  • Chemoembolization, Therapeutic*
  • Disease Progression
  • Humans
  • Liver Neoplasms / drug therapy*
  • Male
  • Receptors, Fibroblast Growth Factor / metabolism
  • Remission Induction
  • Treatment Outcome
  • Triazines / therapeutic use*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Antineoplastic Agents
  • Receptors, Fibroblast Growth Factor
  • Triazines
  • Vascular Endothelial Growth Factor A
  • brivanib
  • Alanine